Nov. 25 at 4:27 PM
$ALT $SNY $IVA $IONS $MDGL
My apologies for the PermaPumpers from the
$ALT board immaturely trying to degrade anything that isn't
$ALT.
This guy @NotLee was Bearish on
$ALT until he saw I posted, and now he wants to hate on me. To his points though:
1) Lancet Publication and AASLD Presentations highlighted that
$ALT admittedly dosed a subject assigned to the Placebo group with the drug (1.2mg Pemvi) and performed an invasive test on a subject that shouldn't have received it.
2) They also highlighted that Weight Loss was less impressive than first reported in 24W top line data.
3) References to independent validation refers to unapproved AI and NITs, not validation of "actual" fibrosis improvement, which, as we know,
$ALT failed miserably.
4) Dual mechanism is useless if the drug doesn't work.
5) Partners/BO speculation is driven by the
$ALT ST board, not merit.
$ALT has consistently said they are Going It Alone (GIA), which
$ALT's recent hires with Commerical experience support.
